Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
Phase 1/2 single-arm trial of axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 CAR T-cell therapy, in refractory large B-cell lymphoma. In 101 treated pivotal patients, 82% responded versus a 20% historical rate (primary endpoint met), and 42.6% were alive at 5 years.
| Status | Completed |
|---|---|
| Phase | Phase 1 2 |
| Primary Endpoint Result | Met |
| Enrollment | 307 |
| Start Date | 2015-04-21 |
| Primary Completion Date | 2023-07-27 |
Results Summary
In ZUMA-1 phase 2 (refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or transformed follicular lymphoma; 111 enrolled, 101 treated with axicabtagene ciloleucel), the investigator-assessed objective response rate at the primary analysis was 82% (95% CI 73–89; P<0.001 against a prespecified 20% historical rate), with 54% complete responses. At the 5-year analysis (data cut 11 August 2021, median follow-up 63.1 months) it was 84 of 101 (83%) with 59 (58%) complete; 31% had an ongoing response, median overall survival was 25.8 months and 5-year overall survival 42.6%. Cytokine release syndrome (CRS) occurred in 93% (grade 3 or higher 11%) and neurologic events in 64% (grade 3 or higher 30%); 4 patients died of adverse events, 2 related to axi-cel. Phase 1: 1 of 6 DLT-evaluable patients had a DLT. Cohorts 3 to 6 (posted results): grade 3 or higher CRS 0% to 3%, response 63% to 95%. No replication-competent retrovirus in 277 participants.
Design Implications
A single dose of autologous anti-CD19 CAR T cells after lymphodepletion can induce remissions lasting more than 5 years in refractory large B-cell lymphoma, mostly in complete responders (median duration 62.2 months, versus 1.9 months for partial responses), so depth of response is the signal to optimize. Durable remission did not need lasting B-cell aplasia: 75% of ongoing responders had detectable B cells at 24 months. Early CAR T-cell expansion predicted durable response, but higher expansion also tracked with grade 3 or higher neurologic events. Late complete responses (23 patients, up to 15 months) argue against early judgment of partial responders. CRS and neurotoxicity are the main liabilities: prophylactic tocilizumab lowered severe CRS but not severe neurotoxicity, while prophylactic dexamethasone with earlier corticosteroid and tocilizumab removed grade 3 or higher CRS without apparent loss of response. Ten of 111 enrolled patients were never treated; bridging was barred.
Rationale
Axicabtagene ciloleucel (axi-cel) is made from the patient's own T cells, transduced with a retroviral vector that encodes a chimeric antigen receptor (CAR): a single-chain variable fragment against CD19 with CD3ζ and CD28 signaling domains. It is given as one intravenous infusion of 2×10^6 CAR T cells/kg after fludarabine and cyclophosphamide lymphodepletion. CD19 is expressed on normal and malignant B cells, including most large B-cell lymphomas; the CAR lets T cells kill them without HLA restriction. Refractory disease responds poorly to chemotherapy (26% response in the SCHOLAR-1 retrospective cohort), so a mechanism independent of chemosensitivity was expected to produce responses.
Limitations
ZUMA-1 was single-arm and open-label with no concurrent control; the response rate was tested against a prespecified 20% historical rate, and independent central review gave a lower rate than investigators (71% vs 82%). Pivotal cohorts treated 101 of 111 enrolled patients. Cohorts 3 to 6 (38 to 50 each) were exploratory, with descriptive primary outcomes and no stated success criterion. Disease assessments after 24 months followed institutional practice.
Registry record
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6). The primary objectives of this study are: * Phase 1 Study: Evaluate the safety of axicabtagene ciloleucel regimens * Phase 2 Pivotal Study; Evaluate the efficacy of axicabtagene ciloleucel * Phase 2 Safety Management Study: Assess the impact of prophylactic regimens or earlier interventions on the rate and severity of cytokine release syndrome (CRS) and neurologic toxicities Subjects who received an infusion of KTE-C19 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968.
| Primary Outcomes | Phase 1 Study: Number of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs), Phase 2 Pivotal Study (Cohorts 1 and 2): Overall Response Rate (ORR) as Assessed by Investigator Per Revised International Working Group (IWG) Response Criteria for Malignant Lymphoma, Phase 2 Safety Management Study (Cohort 3): Percentage of Participants With Treatment-Emergent Cytokine Release Syndrome (CRS) and Neurologic Toxicities by Severity Grades, Phase 2 Safety Management Study (Cohort 4): Percentage of Participants With Treatment-Emergent CRS and Neurologic Toxicities by Severity Grades, Phase 2 Safety Management Study (Cohort 5): Percentage of Participants With Treatment-Emergent CRS and Neurologic Toxicities by Severity Grades, Phase 2 Safety Management Study (Cohort 6): Percentage of Participants With Treatment-Emergent CRS and Neurologic Toxicities by Severity Grades |
|---|---|
| Registry Last Updated | 2024-06-04 |
| Results First Posted Date | 2021-11-23 |
| Minimum Age | 18 Years |
| Modalities | cell_therapy |
| Intervention Names | Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone |
| Allocation | Non Randomized |
| Masking | None |
| Primary Purpose | Treatment |
| Has Results | Yes |
| Acronym | ZUMA-1 |
| Enrollment Type | Actual |
| Countries | United States, Canada, France, Germany, Israel, Netherlands |
| Intervention Types | biological, drug |
| Study Type | Interventional |
| Intervention Model | Sequential |
| Healthy Volunteers | No |
| Condition Terms | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL), Lymphoma, Large B-Cell, Diffuse |
| Completion Date | 2023-07-27 |
| Lead Sponsor Class | Industry |
| Eligibility Sex | All |
Official Title
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma
Eligibility Criteria
Key Inclusion Criteria
-
Histologically confirmed:
- Diffuse Large B Cell Lymphoma (DLBCL)
- Primary Mediastinal Large B Cell Lymphoma (PMBCL)
- Transformation Follicular Lymphoma (TFL)
- High grade B-cell lymphoma (HGBCL)
-
Chemotherapy-refractory disease, defined as one of more of the following:
- No response to last line of therapy i. Progressive disease (PD) as best response to most recent therapy regimen ii. Stable disease (SD) as best response to most recent therapy with duration no longer than 6 month from last dose of therapy OR
- Refractory post-autologous stem cell transplant (ASCT) i. Disease progression or relapsed less than or equal to 12 months of ASCT (must have biopsy proven recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy
-
Individuals must have received adequate prior therapy including at a minimum:
- Anti-cluster of differentiate 20 (CD20) monoclonal antibody unless investigator determines that tumor is CD20-negative and
- an anthracycline containing chemotherapy regimen
- for individual with transformed FL must have chemorefractory disease after transformation to DLBCL.
-
At least one measurable lesion per revised international working group (IWG Response Criteria
-
Eastern cooperative oncology group (ECOG) performance status of 0 or 1
-
Absolute neutrophil count (ANC) ≥ 1000/microliters (uL)
-
Absolute lymphocyte count ≥ 100/uL
-
Platelet count ≥ 75,000/uL
-
Adequate renal, hepatic, pulmonary and cardiac function defined as:
- Creatinine clearance (as estimated by Cockcroft Gault) > 60 mL/min
- Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 upper limit of normal (ULN)
- Total bilirubin < 1.5 mg/dL, except in individuals with Gilbert's syndrome
- Cardiac ejection fraction >50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant pleural effusion
- Baseline oxygen saturation >92% on room air
-
All individuals or legally appointed representatives/caregivers, must personally sign and date the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved consent form before initiating any study specific procedures or activities.
-
Relapsed or refractory large B-cell lymphoma including DLBCL, PMBCL, TFL, and HGBCL after two systemic lines of therapy
Key Exclusion Criteria
- History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years
- History of allogeneic stem cell transplantation
- Prior chimeric antigen receptor (CAR) therapy or other genetically modified T cell therapy
- Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management. Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment
- History of human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B or C infection. Individuals with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines
- Individuals with detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma, cerebrospinal fluid malignant cells or brain metastases
- History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Identifiers & revision
clinicaltrials NCT02348216euclinicaltrials 2015-005007-86
